GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (STU:RTI) » Definitions » E10

Revance Therapeutics (STU:RTI) E10 : €-4.00 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Revance Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Revance Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was €-0.333. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-4.00 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-03-23), Revance Therapeutics's current stock price is €3.44. Revance Therapeutics's E10 for the quarter that ended in Sep. 2024 was €-4.00. Revance Therapeutics's Shiller PE Ratio of today is .


Revance Therapeutics E10 Historical Data

The historical data trend for Revance Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics E10 Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -4.21 -4.16

Revance Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.37 -4.16 -4.10 -4.16 -4.00

Competitive Comparison of Revance Therapeutics's E10

For the Biotechnology subindustry, Revance Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revance Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Shiller PE Ratio falls into.



Revance Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Revance Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.333/133.0289*133.0289
=-0.333

Current CPI (Sep. 2024) = 133.0289.

Revance Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -0.487 99.070 -0.654
201503 -0.601 99.621 -0.803
201506 -0.633 100.684 -0.836
201509 -0.722 100.392 -0.957
201512 -0.762 99.792 -1.016
201603 -0.638 100.470 -0.845
201606 -0.783 101.688 -1.024
201609 -0.570 101.861 -0.744
201612 -0.901 101.863 -1.177
201703 -0.879 102.862 -1.137
201706 -0.801 103.349 -1.031
201709 -0.847 104.136 -1.082
201712 -0.963 104.011 -1.232
201803 -0.787 105.290 -0.994
201806 -0.805 106.317 -1.007
201809 -0.780 106.507 -0.974
201812 -0.984 105.998 -1.235
201903 -0.752 107.251 -0.933
201906 -0.761 108.070 -0.937
201909 -0.872 108.329 -1.071
201912 -0.891 108.420 -1.093
202003 -1.041 108.902 -1.272
202006 -0.995 108.767 -1.217
202009 -1.138 109.815 -1.379
202012 -1.019 109.897 -1.233
202103 -0.907 111.754 -1.080
202106 -0.888 114.631 -1.031
202109 -0.935 115.734 -1.075
202112 -0.823 117.630 -0.931
202203 -0.854 121.301 -0.937
202206 -0.832 125.017 -0.885
202209 -1.182 125.227 -1.256
202212 -1.718 125.222 -1.825
202303 -0.691 127.348 -0.722
202306 -0.738 128.729 -0.763
202309 -1.527 129.860 -1.564
202312 -0.578 129.419 -0.594
202403 -0.534 131.776 -0.539
202406 -0.334 132.554 -0.335
202409 -0.333 133.029 -0.333

Add all the adjusted EPS together and divide 10 will get our e10.


Revance Therapeutics  (STU:RTI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Revance Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics Headlines

No Headlines